EcoDrugPlus

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSSTUG00000050116
Gene Symbol: LOC115173385
3 Cross references
273 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSSTUG00000040342
Gene Symbol: FRK
3 Cross references
156 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSSTUG00000037450
Gene Symbol: FRK
3 Cross references
156 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSSTUG00000012200
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSSTUG00000022793
Gene Symbol: LOC115161893
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSSTUG00000020885
Gene Symbol: LOC115148533
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSSTUG00000010742
Gene Symbol: LOC115153994
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-4-Like

Ensembl ID : ENSSTUG00000003335
Gene Symbol: LOC115167414
3 Cross references
63 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6-Like

Ensembl ID : ENSSTUG00000015727
Gene Symbol: LOC115205692
3 Cross references
63 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6-Like

Ensembl ID : ENSSTUG00000029107
Gene Symbol: LOC115205138
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6-Like

Ensembl ID : ENSSTUG00000042200
Gene Symbol: LOC115171131
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Beta-2-Like

Ensembl ID : ENSSTUG00000015821
Gene Symbol: LOC115205690
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).